Vivian Labovsky1, Norma Alejandra Chasseing2, María Belén Giorello3, Ayelén Matas3, Pablo Marenco4, Kevin Mauro Davies4, Francisco Raúl Borzone3, María de Luján Calcagno5, Hernán García-Rivello4, Alejandra Wernicke4, Leandro Marcelo Martinez6. 1. Laboratorio de Inmunohematología (IBYME) - Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET), Instituto de Biología Y Medicina Experimental, Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, CP 1428, Buenos Aires, Argentina. 16vivian@gmail.com. 2. Laboratorio de Inmunohematología (IBYME) - Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET), Instituto de Biología Y Medicina Experimental, Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, CP 1428, Buenos Aires, Argentina. achasseing@ibyme.conicet.gov.ar. 3. Laboratorio de Inmunohematología (IBYME) - Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET), Instituto de Biología Y Medicina Experimental, Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, CP 1428, Buenos Aires, Argentina. 4. Departamento de Anatomía Patológica, Hospital Italiano, Juan Domingo Perón 4190, Ciudad Autónoma de Buenos Aires, CP 1181, Buenos Aires, Argentina. 5. Facultad de Farmacia Y Bioquímica, Universidad de Buenos Aires, Junín 954, Ciudad Autónoma de Buenos Aires, CP 1113, Buenos Aires, Argentina. 6. Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Abstract
PURPOSE: Dendritic cells (DCs) are the most potent antigen-presenting cells that play a major role in initiating the antitumor immune response in different types of cancer. However, the prognostic significance of the accumulation of these cells in human early breast tumors is not totally clear. The aim of this study is to evaluate the prognostic relevance of CD1a( +) and CD83( +) dendritic cells in early breast cancer patients. METHODS: We conducted immunohistochemical assays to determine the number of stromal CD1a( +) and CD83( +) DCs in primary tumors from early invasive ductal breast cancer patients, and analyzed their association with clinico-pathological characteristics. RESULTS: Patients with high CD1a( +) DC number had lower risk of bone metastatic occurrence, as well as, longer disease-free survival (DFS), bone metastasis-free survival (BMFS) and overall survival (OS). Moreover, CD1a( +) DC number was an independent prognostic factor for BMFS and OS. In contrast, we found that patients with high number of CD83( +) DCs had lower risk of mix (bone and visceral)-metastatic occurrence. Likewise, these patients presented better prognosis with longer DFS, mix-MFS and OS. Furthermore, CD83( +) DC number was an independent prognostic factor for DFS and OS. CONCLUSION: The quantification of the stromal infiltration of DCs expressing CD1a or CD83 in early invasive breast cancer patients serves to indicate the prognostic risk of developing metastasis in a specific site.
PURPOSE: Dendritic cells (DCs) are the most potent antigen-presenting cells that play a major role in initiating the antitumor immune response in different types of cancer. However, the prognostic significance of the accumulation of these cells in human early breast tumors is not totally clear. The aim of this study is to evaluate the prognostic relevance of CD1a( +) and CD83( +) dendritic cells in early breast cancer patients. METHODS: We conducted immunohistochemical assays to determine the number of stromal CD1a( +) and CD83( +) DCs in primary tumors from early invasive ductal breast cancer patients, and analyzed their association with clinico-pathological characteristics. RESULTS: Patients with high CD1a( +) DC number had lower risk of bone metastatic occurrence, as well as, longer disease-free survival (DFS), bone metastasis-free survival (BMFS) and overall survival (OS). Moreover, CD1a( +) DC number was an independent prognostic factor for BMFS and OS. In contrast, we found that patients with high number of CD83( +) DCs had lower risk of mix (bone and visceral)-metastatic occurrence. Likewise, these patients presented better prognosis with longer DFS, mix-MFS and OS. Furthermore, CD83( +) DC number was an independent prognostic factor for DFS and OS. CONCLUSION: The quantification of the stromal infiltration of DCs expressing CD1a or CD83 in early invasive breast cancer patients serves to indicate the prognostic risk of developing metastasis in a specific site.
Authors: François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel Journal: J Exp Med Date: 2005-10-17 Impact factor: 14.307
Authors: D Bell; P Chomarat; D Broyles; G Netto; G M Harb; S Lebecque; J Valladeau; J Davoust; K A Palucka; J Banchereau Journal: J Exp Med Date: 1999-11-15 Impact factor: 14.307
Authors: Joanna Szpor; Joanna Streb; Anna Glajcar; Piotr Sadowski; Anna Streb-Smoleń; Robert Jach; Diana Hodorowicz-Zaniewska Journal: Int J Mol Sci Date: 2022-07-30 Impact factor: 6.208